These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 6893118)

  • 1. Effects of long-term therapy with calcitriol in patients with moderate renal failure.
    Healy MD; Malluche HH; Goldstein DA; Singer FR; Massry SG
    Arch Intern Med; 1980 Aug; 140(8):1030-3. PubMed ID: 6893118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and histological effects of 1,25 dihydroxycholecalciferol (1,25-DHCC) in the osteomalacia of chronic and failure.
    Eastwood JB; Phillips ME; de Wardener HE; Bordier J; Marie P; Arnaud CD; Norman AW
    J Urol Nephrol (Paris); 1974 Dec; 80(12):984-5. PubMed ID: 4617780
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term low-dose calcitriol treatment in predialysis chronic renal failure: can it prevent hyperparathyroid bone disease?
    Nordal KP; Dahl E; Halse J; Attramadal A; Flatmark A
    Nephrol Dial Transplant; 1995; 10(2):203-6. PubMed ID: 7753453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
    Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
    Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of secondary hyperparathyroidism in chronic renal insufficiency.
    Portale AA; Morris RC
    Miner Electrolyte Metab; 1991; 17(4):211-20. PubMed ID: 1813783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome.
    Malluche HH; Goldstein DA; Massry SG
    J Clin Invest; 1979 Mar; 63(3):494-500. PubMed ID: 429568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitriol in disorders of bone and calcium metabolism.
    Riggs BL
    Clin Ther; 1980; 3(1):33-9. PubMed ID: 6893296
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.
    Juergensen PH; Finkelstein FO; Cooper K; Santacroce S; Kliger AS
    Adv Perit Dial; 1993; 9():257-9. PubMed ID: 8105938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of uremic osteoid to vitamin D.
    Memmos DE; Eastwood JB; Harris E; O'Grady A; de Wardener HE
    Kidney Int Suppl; 1982 May; 11():S50-4. PubMed ID: 6956774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
    Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
    Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc metabolism in patients with chronic renal failure during treatment with 1.25-dihydroxycholecalciferol: a controlled therapeutic trial.
    Kiilerich S; Christiansen C; Christensen MS; Naestoft J
    Clin Nephrol; 1981 Jan; 15(1):23-7. PubMed ID: 7214749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Peculiar problems of phosphocalcium metabolism in chronic renal insufficiency].
    Drüeke T
    Rev Prat; 1989 Apr; 39(11):954-8. PubMed ID: 2717868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL; Felsenfeld AJ; Llach F
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism.
    Dressler R; Laut J; Lynn RI; Ginsberg N
    Clin Nephrol; 1995 May; 43(5):324-31. PubMed ID: 7634548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction of PTH and dietary phosphorus and calcium on serum calcitriol levels in the rat with experimental renal failure.
    Martin-Malo A; Rodriguez M; Martinez ME; Torres A; Felsenfeld AJ
    Nephrol Dial Transplant; 1996 Aug; 11(8):1553-8. PubMed ID: 8856210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.